Author

Julien Alberola

Centre National de la Recherche Scientifique

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Molecular Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 1 Research Focus:differential expression· 1 Assay:DNA methylation· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Research Focus:gene regulatory network inference· 1 Organism:human· 1 Approach:statistical model· 1

Frequent Co-Authors

Antonin MarchaisiD· 1 shared Birgit GeoergeriD· 1 shared Fayez IssaiD· 1 shared Guillaume MeuriceiD· 1 shared Hana RaslováiD· 1 shared Iryna PirozhkovaiD· 1 shared Jeremy RichiD· 1 shared Kamel MamchaouiiD· 1 shared

Activity by Year

2024-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperMolecular Biology

Antonin MarchaisORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

DiPRO1 dependent transcriptional and epigenetic regulation distinctly controls the fate of muscle and mesenchymal cancer cells.

Jeremy Rich, Melanie Bennaroch, Laura Notel, Polina Patalakh, Julien Alberola, Fayez Issa, Paule Opolon, Olivia Bawa, Windy Rondof, Antonin Marchais, Philippe Dessen, Guillaume Meurice, Morgane Le Gall, Mélanie Polrot, Karine Ser‐Le Roux, , Iryna Pirozhkova

This paper identifies DiPRO1 as a regulator of myoblast differentiation and mesenchymal tumor suppression through epigenetic and transcriptional mechanisms, showing its potential as a therapeutic target.

EMBO Molecular Medicine · Jul 15, 2024Peer-reviewedMolecular Biology